The Werner syndrome RecQ helicase WRN was identified as a synthetic lethal target in cancer cells with microsatellite instability (MSI) by several genetic screens^1,2,3,4,5,6. Despite advances in treatment with immune checkpoint inhibitors^7,8,9,10, there is an unmet need in the treatment of MSI cancers^11,12,13,14. Here we report the structural, biochemical, cellular and pharmacological characterization of the clinical-stage WRN helicase inhibitor HRO761, which was identified through an innovative hit-finding and lead-optimization strategy. HRO761 is a potent, selective, allosteric WRN inhibitor that binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation. Pharmacological inhibition by HRO761 recapitulated the phenotype observed by WRN genetic suppression, leading to DNA damage and inhibition of tumour cell growth selectively in MSI cells in a p53-independent manner. Moreover, HRO761 led to WRN degradation in MSI cells but not in microsatellite-stable cells. Oral treatment with HRO761 resulted in dose-dependent in vivo DNA damage induction and tumour growth inhibition in MSI cell- and patient-derived xenograft models. These findings represent preclinical pharmacological validation of WRN as a therapeutic target in MSI cancers. A clinical trial with HRO761 (NCT05838768) is ongoing to assess the safety, tolerability and preliminary anti-tumour activity in patients with MSI colorectal cancer and other MSI solid tumours.

通过多次遗传筛选，Werner 综合征 RecQ 解旋酶 WRN 被鉴定为具有微卫星不稳定性 (MSI) 的癌细胞中的合成致死靶标^1,2,3,4,5,6 。尽管免疫检查点抑制剂的治疗取得了进展^7,8,9,10 ，但 MSI 癌症的治疗需求尚未得到满足^11,12,13,14 。在此，我们报告了临床阶段 WRN 解旋酶抑制剂 HRO761 的结构、生化、细胞和药理学特征，该抑制剂是通过创新的命中发现和先导化合物优化策略鉴定的。 HRO761 是一种有效的、选择性的变构 WRN 抑制剂，可结合在 D1 和 D2 解旋酶结构域的界面上，将 WRN 锁定在非活性构象中。 HRO761 的药理抑制重现了 WRN 基因抑制所观察到的表型，导致 DNA 损伤并以不依赖于 p53 的方式选择性地抑制 MSI 细胞中的肿瘤细胞生长。此外，HRO761 会导致 MSI 细胞中的 WRN 降解，但不会导致微卫星稳定细胞中的 WRN 降解。在 MSI 细胞和患者来源的异种移植模型中，口服 HRO761 会导致剂量依赖性的体内 DNA 损伤诱导和肿瘤生长抑制。这些发现代表了 WRN 作为 MSI 癌症治疗靶点的临床前药理学验证。 HRO761 (NCT05838768) 的临床试验正在进行中，以评估 MSI 结直肠癌和其他 MSI 实体瘤患者的安全性、耐受性和初步抗肿瘤活性。